Fruquintinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 59 clinical trials, of which 17 were completed, 27 are ongoing, and 15 are planned.
Fruquintinib is an anti cancer agent. Fruquintinib is a selective, small molecule tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3. The vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play a pivotal role in tumor-related angiogenesis. Inhibition of VEGF signaling in tumor vasculature represents an exciting therapeutic strategy, with the potential to arrest the development of new blood vessels essential for tumor growth and metastasis.
The revenue for Fruquintinib is expected to reach a total of $10.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fruquintinib NPV Report.
Fruquintinib (Elunate) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Elunate is indicated for the treatment of metastatic colorectal cancer patients, who have failed at least two prior systemic antineoplastic therapies including fluoropyrimidine, oxaliplatin and irinotecan, with or without prior use of anti-vascular endothelial growth factor or anti-epidermal growth factor receptor therapies.
Fruquintinib (HMPL-013) is under development for the treatment of locally advanced rectal cancer, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma, angiosarcoma, soft tissue sarcoma, advanced or metastatic triple negative breast cancer, HER2 negative breast cancer, metastatic colorectal adenocarcinoma, metastatic renal cell carcinoma, metastatic biliary tract adenocarcinoma, advanced solid tumor including gastric cancer, gastroesophageal junction adenocarcinoma and advanced non squamous non small cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, advanced or recurrent/metastatic pancreatic adenocarcinoma and meningioma. It is administered orally. It was also under development for hepatocellular carcinoma and thymic cancer.
Eli Lilly and Co Overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.
Quick View – Fruquintinib
|Highest Development Stage|